Author

E. Tucker

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Ecology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:ecology & biodiversity· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Bellini· 1 shared A. Carcaboso· 1 shared A. Dunbar· 1 shared A. Goodman· 1 shared A. Karzai· 1 shared A. Krishnan· 1 shared A. R. Migliaccio· 1 shared A. Saint-Charles· 1 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Bellini

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

COMBINATION THERAPIES TARGETING ALK-ABERRANT NEUROBLASTOMA IN PRECLINICAL MODELS.

E. Tucker, I. Jimenez, L. Chen, A. Bellini, C. Gorrini, E. Calton, Q. Gao, H. Che, E. Poon, Y. Jamin, B. Martins da Costa, K. Barker, S. Shrestha, C. Hutchinson, S. Dhariwal, , G. Schleiermacher

This study evaluates lorlatinib, an ALK inhibitor, in combination with chemotherapy or idasanutlin in preclinical neuroblastoma models, finding synergy in models with high ALK expression.

Clinical Cancer Research · Apr 3, 2023Peer-reviewedCancer Biology

A century of sampling at an ecological preserve reveals declining diversity of wild bees

K. K. Graham, P. Glaum, J. Hartert, J. Gibbs, E. Tucker, R. Isaacs, F. S. Valdovinos

The paper analyzes wild bee diversity over a century at a preserve, finding declining species richness and traits associated with extinction risk.

bioRxiv · Jan 15, 2023 · PreprintEcology

CXCL8/CXCR2 signaling mediates bone marrow fibrosis and represents a therapeutic target in myelofibrosis

A. Dunbar, D. Kim, M. Lu, M. Farina, J. L. Yang, Y. Park, F. Gobbo, P. Verachi, F. Martelli, A. Karzai, W. Xiao, L. Xia, N. Elmansy, M. Kleppe, Z. Chen, , R. Hoffman

This study identifies CXCL8/CXCR2 signaling as a driver of bone marrow fibrosis in myelofibrosis and shows its therapeutic potential through genetic and pharmacologic inhibition.

bioRxiv · Dec 8, 2021Cancer Biology